Tapan Kadia, MD
Disclosures: Grant or research support-Bristol-Myers Squibb|Grant or research support-Pfizer, Inc.|Grant or research support-Other-Abbvie|Grant or research support-Other-Amgen|Grant or research support-Genentech, Inc.|Grant or research support-Other-Ascentage|Grant or research support-Other-Cellenkos|Grant or research support-AstraZeneca|Grant or research support-Other-Astellas|Paid consultant-Other-Abbvie|Paid consultant-Genentech, Inc.|Grant or research support-Other-Jazz|Paid consultant-Other-Jazz|Paid consultant-Novartis AG|Paid consultant-Daiichi Sankyo|Paid consultant-Other-Agios|Paid consultant-Pfizer, Inc. - 01/28/2021

Dr. Tapan Kadia is Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.  In addition to being the associate program director of the leukemia fellowship program, he is actively involved in clinical and translational research for the treatment of patients with leukemia.  His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL.  He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these.  He has received numerous academic and clinical honors and awards for his studies and clinical research.  Additionally, he’s authored over 350 peer-reviewed articles, numerous abstracts, and has been invited to speak nationally and internationally about his work.